Angiofibromas are a group of benign tumors that share a basic architectural theme under the microscope: a mixture of blood vessels and fibrous connective tissue. Despite that shared blueprint, the term “angiofibroma” applies to several clinically distinct entities that arise in different body sites, affect different patient populations, and carry different molecular signatures. The histology of each type has its own diagnostic quirks, and understanding those differences matters because misidentification can lead to unnecessary treatment or missed associations with genetic syndromes.
Juvenile Nasopharyngeal Angiofibroma Under the Microscope
Juvenile nasopharyngeal angiofibroma (JNA) is the most studied member of the angiofibroma family. It arises almost exclusively in adolescent males, originating from the area around the sphenopalatine foramen in the back of the nasal cavity. Under the microscope, JNA shows a characteristic two-component (biphasic) pattern: a highly vascular proliferation set within a fibrous stroma populated by distinctive plump, angulated, and stellate-shaped cells that are classified as fibroblasts.1PubMed Central. Nasopharyngeal Angiofibroma: A Clinical, Histopathological and Immunohistochemical Study of 42 Cases with Emphasis on Stromal Features The collagen fibers running through the stroma tend to be arranged in a somewhat disorganized fashion, interspersed with spindle-shaped cells, rather than in the neatly bundled parallel pattern seen in many other fibrous tumors.2PubMed Central. Juvenile nasopharyngeal angiofibroma
The blood vessels in JNA are a defining feature and also the source of the tumor’s most dramatic clinical problem: severe nosebleeds. These vessels range from small capillary-sized channels to large, irregularly shaped spaces, and many of them lack the smooth muscle layer that normal blood vessels use to constrict and control bleeding. That absence of a proper muscular wall means the vessels cannot clamp down when disrupted. It is why even a biopsy of JNA can cause dangerous hemorrhage, and why surgeons typically rely on imaging and clinical presentation rather than tissue sampling for initial diagnosis.
How JNA Stroma Changes Between New and Recurrent Tumors
The stromal component of JNA is not static. Electron microscopy and detailed histologic studies have shown that the appearance of the stroma differs depending on whether you are looking at a tumor presenting for the first time or one that has come back after surgery. In first-time tumors, the stroma tends to look more organized and less cellular, with scar-like areas, neatly arranged collagen bundles, and fusiform (spindle-shaped) stromal cells predominating. Recurrent tumors, by contrast, show a shift toward higher cellularity, with more stellate stromal cells, thicker vessel walls, and a greater density of mast cells.3PubMed. Electron microscopy of juvenile nasopharyngeal angiofibroma: clinical and histopathological correlates
That shift matters for a practical reason. Recurrence in JNA is a real concern: risk factors include the size of the original tumor, whether it invaded the sphenoid bone, and what surgical approach was used. Patients who had endoscopic removal without sphenoid bone involvement tend to enjoy the longest time before any relapse.4PubMed Central. Risk Factors and Characteristics of the Recurrence of Juvenile Nasopharyngeal Angiofibroma: A 22-Year Experience With 123 Cases at a Tertiary Center The histologic differences between primary and recurrent tumors suggest that the tumor microenvironment remodels over time, and some researchers think the mast-cell-rich, highly cellular stroma in recurrences might reflect a more aggressive or treatment-resistant biology.
Mast Cells and Immune Cells in JNA Stroma
One underappreciated feature of JNA histology is the surprisingly large population of mast cells embedded in the stroma. In one detailed study, mast cells made up about 15 percent of all cells within the tumor. The vast majority of those mast cells co-expressed both tryptase and chymase, a subtype that was present at significantly higher levels in JNA tissue compared to normal nasal mucosa. CD8-positive T cells were also more abundant in the tumor than in surrounding healthy tissue.5SpringerLink / European Archives of Oto-Rhino-Laryngology. Mast cells and T-lymphocytes in juvenile angiofibromas
Mast cells release a cocktail of chemicals that promote blood vessel formation, tissue remodeling, and local inflammation. Their abundance in JNA likely contributes to the rich vascular network that defines the tumor. The elevated mast cell density in recurrent cases in particular raises the question of whether these immune cells play a role in driving regrowth after surgery, though that connection remains speculative for now.
Immunohistochemistry and Molecular Markers of JNA
When pathologists need to confirm a diagnosis of JNA or distinguish it from a look-alike, they turn to immunohistochemical stains. The endothelial cells lining JNA blood vessels stain positive for endoglin, VEGFC, and FLI-1, all markers associated with active blood vessel biology. Podoplanin and VEGFR3, markers associated with lymphatic vessels, are negative across the board, indicating that JNA’s vascular network is purely blood-vessel-derived rather than lymphatic.6Spandidos Publications / Exp Ther Med. Markers of vascular differentiation, proliferation and tissue remodeling in juvenile nasopharyngeal angiofibromas
One especially useful stain in clinical practice is GLUT-1, a glucose transporter protein. Infantile hemangiomas, a common vascular tumor of infancy that sometimes enters the differential diagnosis, stain strongly positive for GLUT-1. JNA, along with vascular malformations, is GLUT-1-negative. That single stain can quickly separate these entities when clinical context is ambiguous.7Spandidos Publications / Exp Ther Med. Markers of vascular differentiation, proliferation and tissue remodeling in juvenile nasopharyngeal angiofibromas
At the genetic level, JNA stromal cells show a striking abnormality in the beta-catenin pathway. In a study of 16 tumors, nuclear accumulation of beta-catenin protein was found diffusely in the stromal cells (but not in the endothelial cells) of every single case. Activating mutations in the beta-catenin gene were present in 75 percent of cases, and identical mutations showed up in tumors that later recurred, suggesting these mutations drive tumor development rather than appearing as a secondary event.8PubMed Central. Frequent beta-catenin mutations in juvenile nasopharyngeal angiofibromas Beta-catenin signaling sits at the center of a pathway that controls cell growth and tissue patterning during development, which fits with JNA’s predilection for adolescent males during a period of active craniofacial growth.
Why JNA Is Almost Exclusively a Disease of Adolescent Males
The near-total restriction of JNA to male adolescents has long suggested a hormonal component. These tumors harbor large numbers of androgen receptors, and the hypothesis is that their growth is hormonally driven, with rising testosterone levels during puberty fueling expansion.9PubMed Central. Early-onset juvenile nasopharyngeal angiofibroma (JNA): a systematic review The combination of androgen receptor expression and activating beta-catenin mutations creates a picture of a tumor sitting at the intersection of hormonal signaling and developmental pathway disruption. That overlap helps explain why JNA tends to stabilize or even regress after puberty in some patients, as the hormonal stimulus diminishes.
Cutaneous Angiofibroma and the Fibrous Papule
Step away from the nasopharynx and onto the skin, and you encounter a completely different clinical entity that shares the name. Cutaneous angiofibromas include the common fibrous papule of the nose and the facial angiofibromas seen in tuberous sclerosis complex (TSC). A fibrous papule is a small, firm, dome-shaped bump on or near the nose that is entirely benign and usually removed for cosmetic reasons. Under the microscope, the diagnosis is typically straightforward: a fibrous papule shows the hallmark architecture of an angiofibroma, with proliferating fibroblast-like stromal cells and dilated blood vessels set in a fibrous dermis.10PubMed. Fibrous Papule: A Histopathologic Review
What makes these lesions more interesting than their bland appearance suggests is their molecular biology. Both sporadic fibrous papules and TSC-associated angiofibromas show activation of the mTOR signaling pathway. In a comparative study, activated forms of key mTOR pathway proteins were highly expressed in the dermal stromal cells and overlying skin cells of both fibrous papules and TSC angiofibromas, while normal skin showed no such activation.11PLoS ONE. Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy? This matters clinically because mTOR inhibitors such as topical rapamycin (sirolimus) have been used to shrink TSC-associated facial angiofibromas. The finding that sporadic fibrous papules share the same pathway activation raises the possibility that the same drugs could treat non-syndromic lesions, though this is not yet standard practice.
For a dermatopathologist, the key diagnostic task when examining a facial angiofibroma is determining whether the patient might have TSC. A solitary fibrous papule on the nose of a middle-aged adult is a clinically trivial finding. Multiple facial angiofibromas on a teenager, especially when accompanied by other skin findings, are a red flag for TSC. The histology of the individual lesions looks essentially the same in both situations, so the distinction rests on clinical context and the number and distribution of lesions rather than on anything the microscope alone can reveal.
Cellular Angiofibroma of the Genital Region
Cellular angiofibroma is a soft tissue tumor that most often arises in the vulva, inguinal region, or scrotum. It is benign and typically presents as a painless, slow-growing lump. Under the microscope, it consists of bland spindle-shaped cells arranged alongside short bundles of wispy collagen and numerous small-to-medium-sized blood vessels with conspicuously thick walls. Most tumors are well-circumscribed, though rare cases show infiltration into surrounding tissue. Intralesional fat is present in a minority of cases, and while occasional mild cellular atypia or scattered mitotic figures can appear, significant atypia and abnormal mitoses are absent.12The American Journal of Surgical Pathology. Cellular Angiofibroma: Clinicopathologic and Immunohistochemical Analysis of 51 Cases
Immunohistochemistry helps distinguish cellular angiofibroma from its many mimics in the genital soft tissue. In a large review, tumor cells were consistently negative for S-100 protein, effectively ruling out nerve sheath tumors. CD34, a marker often seen in fibroblastic tumors, was positive in about half to 60 percent of cases depending on the series. Smooth muscle actin and desmin, markers of muscle differentiation, were positive in only a small minority, suggesting that despite appearing spindle-shaped, the cells are fibroblasts rather than myofibroblasts.13PubMed Central. Cellular angiofibroma in women: a review of the literature An intriguing feature of cellular angiofibroma is that many tumors express estrogen and progesterone receptors, hinting at a hormonal influence on their biology.14PubMed Central. Cellular angiofibroma in women: a review of the literature This parallels JNA’s androgen receptor expression, suggesting that hormonal sensitivity may be a broader theme across the angiofibroma family, even though the specific hormones and body sites involved are completely different.
The main diagnostic challenge with cellular angiofibroma is its location. It shares anatomical territory with aggressive angiomyxoma, spindle cell lipoma, and solitary fibrous tumor. Aggressive angiomyxoma, in particular, can look deceptively similar and has a much higher recurrence rate. The thick-walled vessels and well-defined border of cellular angiofibroma, combined with its immunoprofile, usually allow reliable separation, but pathologists need to be aware of the overlap.
Soft Tissue Angiofibroma and Its Molecular Signature
Soft tissue angiofibroma (STAF) is the newest member of the angiofibroma family, first described in 2012. It arises in the extremities and trunk, usually presenting as a painless, slowly growing mass in the subcutaneous fat or deep soft tissue of adults. On low-power examination, STAF is well-circumscribed and sometimes partially encapsulated, with a vaguely lobulated architecture that alternates between hypocellular, myxoid (mucus-rich) zones and more densely cellular, collagenous zones. At higher magnification, the tumors consist of uniform, bland spindle cells accompanied by a prominent vascular network of countless small, thin-walled, frequently branching blood vessels.15PubMed Central. Angiofibroma of Soft Tissue: A Clinicopathological Study of Eight Cases With Emphasis on the Diagnostic Utility of Fluorescence In Situ Hybridization Detection for NCOA2 Rearrangement
What sets STAF apart diagnostically is its molecular genetics. The tumor carries a recurrent chromosomal rearrangement involving the NCOA2 gene. In the largest published series, NCOA2 rearrangement was detected by fluorescence in situ hybridization in about 88 percent of cases.16PubMed Central. Angiofibroma of Soft Tissue: A Clinicopathological Study of Eight Cases With Emphasis on the Diagnostic Utility of Fluorescence In Situ Hybridization Detection for NCOA2 Rearrangement The most common fusion partner is the AHRR gene, and the resulting AHRR-NCOA2 fusion transcript was found in roughly two-thirds of cases tested by molecular methods.17PubMed. Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases Detecting this fusion is increasingly used as a confirmatory diagnostic tool, particularly in cases where the morphology is ambiguous.
STAF’s broad differential diagnosis includes low-grade myxoid tumors, solitary fibrous tumor, and even low-grade fibromyxoid sarcoma. The alternating myxoid and collagenous zones can raise concern for a malignant process, but STAF is benign and typically cured by simple excision. Rare cases with increased cellularity and mild cytologic atypia have been reported, but even in those instances the tumors showed the characteristic AHRR-NCOA2 fusion and behaved in a benign fashion, with no metastases or necrosis observed.18Human Pathology: Case Reports. Soft tissue angiofibroma with atypical features The identification of this fusion has been a genuine diagnostic advance, because before molecular testing was available, many of these tumors were probably lumped in with other bland spindle-cell neoplasms and never correctly classified.
How the Different Angiofibromas Compare
Despite sharing a name and a general “vessels plus fibrous tissue” architecture, the various angiofibromas are biologically distinct entities with different driving mutations, different patient demographics, and different clinical behaviors. A brief comparison clarifies what unites and separates them:
- JNA: Arises in the nasopharynx of adolescent males; driven by beta-catenin mutations and androgen receptor signaling; highly vascular with vessels lacking smooth muscle; risk of significant surgical bleeding; recurrence tied to sphenoid bone involvement.
- Cutaneous angiofibroma: Arises on the face; driven by mTOR pathway activation; histologically bland; solitary lesions are trivial, but multiple lesions signal tuberous sclerosis complex.
- Cellular angiofibroma: Arises in the genital region of both sexes; characterized by thick-walled vessels and CD34 positivity; hormone-receptor positive; benign with rare recurrence.
- Soft tissue angiofibroma: Arises in the limbs and trunk; characterized by alternating myxoid and collagenous zones with prominent thin-walled branching vessels; defined by NCOA2 rearrangement; benign and cured by excision.
The common thread is that each tumor is built from fibroblastic or fibroblast-like stromal cells and an abnormal vascular component, but the specific cell signaling gone awry is different in each case. That distinction has practical consequences: you would not screen a patient with a vulvar cellular angiofibroma for beta-catenin mutations, nor would you test a JNA for NCOA2 rearrangement. Each entity has its own diagnostic workup, its own set of mimics to rule out, and its own clinical follow-up plan.
When Histology Alone Is Not Enough
A recurring theme across the angiofibroma family is that histologic appearance can overlap substantially with other tumors, making ancillary testing essential. JNA’s biphasic pattern can resemble other nasopharyngeal tumors, including sinonasal hemangiopericytoma and lobular capillary hemangioma, particularly in small biopsy specimens. Cellular angiofibroma’s spindle-cell morphology and genital location place it squarely in the differential with aggressive angiomyxoma, a tumor that demands wider excision and closer follow-up. Soft tissue angiofibroma’s myxoid zones can mimic low-grade fibromyxoid sarcoma, a malignancy that behaves very differently.
In each of these scenarios, immunohistochemistry provides the first line of clarification, and molecular testing serves as the definitive tiebreaker when needed. The GLUT-1 stain separating JNA from hemangioma, the CD34 and desmin profile distinguishing cellular angiofibroma from its mimics, and the NCOA2 FISH test confirming soft tissue angiofibroma are all examples of how modern pathology uses layered diagnostic tools. No single stain or test is infallible on its own, but the combination of morphology, immunoprofile, and molecular data leaves relatively little room for diagnostic error when all three are applied thoughtfully. The trend in diagnostic pathology is toward integrating these layers earlier in the workup rather than treating molecular testing as a last resort, and angiofibromas as a group illustrate why that approach works.